Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.

In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.

Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.

Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.

However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.